Michael J. Sarrasin Brings Over 20 Years of Clinical, Quality Assurance and Regulatory Experience in Medical Device and Life Sciences Industries
CARLSBAD, Calif., May 4, 2010 (GlobeNewswire via COMTEX News Network) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today that Michael J. Sarrasin, who has over 20 years of clinical, quality assurance and regulatory affairs experience in the medical device and life sciences industries, has been named the Company's Vice President, Clinical, Quality and Regulatory.
In this newly created position Mr. Sarrasin will be responsible for providing overall strategic direction and leadership to Alphatec Spine's global clinical, quality assurance and regulatory affairs groups.
Most recently, Mr. Sarrasin served as Vice President, Regulatory Affairs and Quality Assurance for I-Flow Incorporated, a Lake Forest, CA-based medical device infusion pump manufacturer. In that position, he was responsible for formulating and implementing all of I-Flow's regulatory and quality assurance strategies and programs.
Prior to joining I-Flow, Mr. Sarrasin served in vice-president level positions at several other medical device and life science companies, including Celerus Diagnostics Incorporated, DAKO USA Incorporated and LySonix Incorporated.
"We are pleased to have Mike Sarrasin join our management team and we feel as though he will be a tremendous asset for Alphatec Spine," said Dirk Kuyper, the Company's President and CEO. "He has over two decades of experience in the medical device and life science industries, and has led clinical, quality assurance and regulatory affairs departments for several successful companies. We believe that Mike's expertise will provide us with the necessary leadership in an environment in which the path to regulatory approval for products seems to be becoming less predictable, especially as we continue to bring our novel and innovative products to both the U.S. and international spine market."
